МНОГОЦЕЛЕВОЙ ПОДХОД К КУПИРОВАНИЮ БОЛИ ПРИ ПОРАЖЕНИЯХ МЯГКИХ ТКАНЕЙ

Скачать статью в PDF
Номер журнала: 
11
Год издания: 
2016

None

Основной симптом повреждения мягких тканей – боль, которая может возникнуть по многим причинам. Использование обычных обезболивающих средств может замаскировать боль, что способно привести к ухудшению состояния, препятствовать выздоровлению и потенциально способствовать возникновению новых повреждений. Применение препарата Траумель С – альтернативный подход к лечению воспаления и устранения боли.

Ключевые слова: 
травматология
поражение мягких тканей
боль
нестероидные противовоспалительные препараты
Траумель С

Для цитирования
МНОГОЦЕЛЕВОЙ ПОДХОД К КУПИРОВАНИЮ БОЛИ ПРИ ПОРАЖЕНИЯХ МЯГКИХ ТКАНЕЙ . Врач, 2016; (11): 42-46


It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. Speed C., Hazleman B., Dalton S. Fast Facts: Soft Tissue Disorders, 2nd ed. / Oxford: Health Press Limited, 2006.
  2. Selvanetti A. Overuse tendon injuries: basic science and classification // Operat. Tech. Sports Med. – 1997; 5: 110–7.
  3. Bahr R. No injuries, but plenty of pain? On the methodology for recording overuse symptoms in sports // Br. J. Sports Med. – 2009; 43: 966–72.
  4. van Tulder M., Malmivaara A., Koes B. Repetitive strain injury // Lancet. – 2007; 369: 1815–22.
  5. Laker S., Sullivan W., Strum S. Overuse injury // Medscape. – 2008. Available at: http://emedicine.medscape.com/article/313121-Overview
  6. Paoloni J., Milne C., Orchard J. et al. Non-steroidal anti-inflammatory drugs in sports medicine: guidelines for practical but sensible use // Br. J. Sports Med. – 2009; 43: 863–5.
  7. Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials // Lancet. – 2013; 382: 769–79.
  8. Trelle S., Reichenbach S., Wandel S. et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network analysis // BMJ. – 2011; 342: 7086.
  9. Castellsague J., Riera-Guardia N., Calingaert B. et al. on behalf of the investigators of the Safety of Non-Steroidal Anti-inflammatory Drugs (SOS) Project. Individual NSAIDs and upper gastrointestinal complications. A systematic review and metaanalysis of observational studies (the SOS Project) // Drug Saf. – 2012; 35: 1127–45.
  10. Barkin R., Beckerman M., Blum S. et al. Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult? // Drugs Aging. – 2010; 27: 775–89.
  11. Evans J., McMahon A., McGilchrist M. et al. Topical nonsteroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case–control study // BMJ. – 1995; 311: 22–6
  12. Antman E., Bennett J., Daugherty A. et al. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association // Circulation. – 2007; 115: 1634–42.
  13. Evans J., McGregor E., McMahon A. et al. Nonsteroidal anti-inflammatory drugs and hospitalization for acute renal failure // QJM. – 1995; 88: 551–7.
  14. Laine L., Goldkind L., Curtis S. et al. How common is diclofenacassociated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial // Am. J. Gastroenterol. – 2009; 104: 356–62.
  15. Barkin R. Topical nonsteroidal anti-inflammatory drugs: the importance of drug, delivery, and therapeutic outcome // Am. J. Ther. – 2012: published online 22 February 2012, doi: 10.1097/MJT.0b013e3182459abd
  16. FitzGerald G., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2 // N. Engl. J. Med. – 2001; 345: 433–42.
  17. Brewer A., McCarberg B., Argoff C. Update on the use of topical NSAIDs for the treatment of soft tissue and musculoskeletal pain: a review of recent data and current treatment options // Phys. Sportsmed. – 2010; 38: 62–70.
  18. Kienzler J., Gold M., Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers // J. Clin. Pharmacol. – 2010; 50: 50–61.
  19. Heyneman C., Lawless-Liday C., Wall G. Oral versus topical NSAIDs in rheumatic diseases: a comparison // Drugs. – 2000; 60: 555–74.
  20. Argoff C. Topical analgesics in the management of acute and chronic pain // Mayo Clin. Proc. – 2013; 88: 195–205.
  21. Singh P., Roberts M. Skin permeability and local tissue concentrations of nonsteroidal anti-inflammatory drugs after topical application // J. Pharmacol. Exp. Ther. – 1994; 268: 144–51.
  22. Radermacher J., Jentsch D., Scholl M. et al. Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease // Br. J. Clin. Pharmacol. – 1991; 31: 537–41.
  23. Brune K. Persistence of NSAIDs at effect sites and rapid disappearance from side-effect compartments contributes to tolerability // Curr. Med. Res. Opin. – 2007; 23: 2985–95.
  24. Wolfe M., Lichenstein D., Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs // N. Engl. J. Med. – 1999; 340: 1888–99.
  25. McGettigan P., Henry D. Cardiovascular risk with nonsteroidal anti-inflammatory drugs: systematic review of populationbased controlled observational studies // PLoS Med. – 2011; 8: e1001098.
  26. Barbe M., Barr A. Inflammation and the pathophysiology of work-related musculoskeletal disorders // Brain Behav. Immun. – 2006; 20: 423–9.
  27. Barr A., Barbe M., Clark B. Systemic inflammatory mediators contribute to widespread effects in work-related musculoskeletal disorders // Exerc. Sport Sci. Rev. – 2004; 32: 135–42.
  28. Muller-Wohlfahrt H.-W., Haensel L., Mithoefer K. et al. Terminology and classification of muscle injuries in sport: the Munich consensus statement // Br. J. Sports Med. – 2013; 47: 342–50.
  29. Ziltener J.-L., Leal S., Fournier P.-E. Non-steroidal anti-inflammatory drugs for athletes: an update // Ann. Phys. Rehab. Med. – 2010; 53: 278–88.
  30. Orchard J., Best T., Muller-Wohlfahrt H.-W. et al. The early management of muscle strains in the elite athlete: best practice in a world with a limited evidence basis // Br. J. Sports Med. – 2008; 42: 158–9.
  31. Orchard J., Best T. The management of muscle strain injuries: an early return versus the risk of recurrence // Clin. J. Sports Med. – 2002; 12: 3–5.
  32. Kannus P., Parkkari J., Jarvinen T. et al. Basic science and clinical studies coincide: active treatment approach is needed after a sports injury // Scand. J. Med. Sci. Sports. – 2003; 13: 150–4.
  33. Cesnulevicius K. The bioregulatory approach to work-related musculoskeletal disorders: using the multicomponent ultra low-dose medication Traumeel to target the multiple pathophysiological processes of the disease // Altern. Ther. Health Med. – 2011; 17 (Suppl. 2): S8–17.
  34. Lussignoli S., Bertani S., Metelmann H. et al. Effect of Traumeel S, a homeopathic formulation, on blood-induced inflammation in rats // Complement. Ther. Med. – 1999; 7: 225–30.
  35. Zell J., Connert W., Mau J. et al. Behandlung von akuten Sprunggelenksdistorsionen: doppelblindstudie zum wirksamkeitsnachweis eines homoopathischen Salbenpraparats // Fortschr. Med. – 1988; 106: 96–100.
  36. Bohmer D., Ambrus P. Treatment of sports injuries with Traumeel ointment: a controlled double-blind study // Biol. Ther. – 1992; 10: 290–300.
  37. Thiel W., Borho B. Posttraumatische Kniegelenksergusse und intra-artikulare Traumeel Injektion // Orthopadische Praxis. – 1991; 11: 721–5.
  38. Orizola A., Vargas F. The efficacy of Traumeel S versus diclofenac and placebo ointment in tendinous pain in elite athletes: a randomized controlled trial // Med. Sci. Sports Med. Exerc. – 2007; 39 (5 Suppl.): S79, abstract 858.
  39. Gonzalez de Vega C., Speed C., Wolfarth B. et al. Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: a multicentre, randomised, blinded, controlled and non-inferiority trial // Int. J. Clin. Pract. – 2013; 67: 979–89.
  40. Wolfarth B., Gonzalez de Vega C. Make an impact on your daily practice: the potential role for a natural multi-target medication // Curr. Med. Res. Opin. – 2013; 29 (Suppl. 2): 15–9.
  41. Schneider C. Traumeel – an emerging option to nonsteroidal anti-inflammatory drugs in the management of acute musculoskeletal injuries // Int. J. Gen. Med. – 2011; 4: 225–34.